For most of the modern psychedelic era, the United States government funded none of the clinical work. A review of NIH RePORTER, the agency’s grant database, found zero NIH grants directly funding psychedelic-assisted therapy clinical trials from 2006 to 2020, even as private companies and overseas funders poured money into the field. That is no longer true, and the shape of what changed is more informative than the fact of it. The federal psychedelic portfolio that has formed since 2023 is not a smaller copy of the industry pipeline. It funds different indications, different settings, and different molecules, and the differences are deliberate.
From zero to a portfolio
The turn began in late 2023, when NIDA opened a funding opportunity to develop psychedelics into treatments for substance use disorder, defining psychedelics broadly to include psilocybin, LSD, MDMA, ketamine, and iboga-based compounds, and using a phased grant mechanism designed for high-technical-risk projects that pays out in stages against milestones. The first direct federal awards followed in 2024. NIDA committed up to roughly $14 million to Gilgamesh Pharmaceuticals to develop a novel psychedelic compound, and about $15 million to New York University for a psychedelic therapy trial. The Department of Veterans Affairs issued its own psychedelic grants the same year. A separate $2.4 million NIDA award went to a team at the Medical College of Wisconsin, the University of California San Diego, and LSU Health Shreveport to study psychedelics for methamphetamine addiction. In February 2026, NIDA made its first award to study legal psilocybin services in community settings, the five-year Oregon project the desk has covered separately.
In two years the federal position moved from nothing to a recognizable set of bets. The bets share a shape.
Three ways it differs from the industry pipeline
The first difference is indication. The lead federal funder here is NIDA, the addiction institute, and its money skews heavily toward substance use disorder rather than the depression and post-traumatic stress indications that dominate company programs. Compass Pathways is running psilocybin in treatment-resistant depression. The federal grants are studying psychedelics for tobacco, alcohol, methamphetamine, and broader substance use. These are not the same market, and in several cases they are not a market at all, which is precisely why public money is doing the work.
The second difference is the question being asked. Company trials are built to support registration: tightly controlled efficacy studies aimed at an FDA label. A meaningful share of the federal portfolio is aimed instead at real-world safety and effectiveness, the Oregon community study being the clearest example, asking what happens when these drugs are used outside the controlled conditions that produce registrational data. That is a public-health question more than a commercial one, and it is unlikely to be funded by anyone with a product to sell.
The third difference is the molecule. NIDA’s phased mechanism exists specifically to fund high-risk development, and some of its money is going to compounds that private investors avoid. The Gilgamesh award supports a novel agent, and federal interest has extended to ibogaine analogs, long-acting and difficult compounds that carry safety and development risk most venture capital will not absorb. Where industry concentrates on a small number of de-risked molecules with clear regulatory paths, the federal portfolio is willing to fund the chemistry that does not yet have one.
Why the shape makes sense
None of this is accidental. NIDA’s mandate is addiction, which channels its psychedelic spending toward substance use. The federal government has long operated under constraints on promoting the legalization of Schedule I substances, which pushes its grants toward safety, mechanism, and addiction rather than advocacy-adjacent efficacy claims. And the general logic of public research funding is to address gaps the market will not, which is exactly what funding novel molecules and real-world safety studies does. The result is a portfolio that complements the company pipeline instead of duplicating it. Industry answers whether a specific psilocybin formulation can clear the FDA for depression. The NIH is answering whether psychedelics can treat addiction, whether they are safe as states actually deploy them, and whether riskier compounds are worth developing at all.
The scale caveat
This portfolio is real but small. The federal awards described here total in the tens of millions of dollars, against the hundreds of millions of private capital that flowed into psychedelic companies in the first half of 2024 alone before the investor enthusiasm cooled sharply later that year. That cooling is part of why the federal and philanthropic money now matters more at the margin than the raw figures suggest: when private inflows dropped, public and nonprofit funders became a larger share of what keeps non-commercial research moving. The federal commitment also remains exposed to political direction, and could expand or contract with changes in leadership and appropriations.
How to read it
The practical takeaway for anyone tracking the field is that the company pipelines and the federal portfolio answer different questions, and reading only the first misses half the picture. If you want to know which psychedelic products may reach the market in the next few years, watch the industry programs and their FDA timelines. If you want to know what the next decade of non-commercial psychedelic evidence will actually cover, addiction indications, real-world safety, and novel molecules, read the NIH grants. The two are diverging on purpose, and the divergence is the most useful thing about the federal money.